$HBIO
HARVARD BIOSCIENCE INC

2018 Q1 Form 10-Q Financial Statement

#000117184318003819 Filed on May 10, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1 2016 Q4
Revenue $26.76M $18.09M $26.42M
YoY Change 47.95% -32.92% -6.89%
Cost Of Revenue $13.49M $8.509M $14.31M
YoY Change 58.54% -39.3% -7.35%
Gross Profit $13.27M $9.577M $12.11M
YoY Change 38.55% -26.02% -6.34%
Gross Profit Margin 49.59% 52.95% 45.83%
Selling, General & Admin $11.03M $8.266M $10.26M
YoY Change 33.44% -25.19% -0.39%
% of Gross Profit 83.13% 86.31% 84.76%
Research & Development $2.402M $1.285M $1.160M
YoY Change 86.93% -9.82% -24.18%
% of Gross Profit 18.1% 13.42% 9.58%
Depreciation & Amortization $495.0K $306.0K $990.0K
YoY Change 61.76% -20.52% -22.05%
% of Gross Profit 3.73% 3.2% 8.18%
Operating Expenses $14.54M $9.927M $13.23M
YoY Change 46.42% -24.6% 3.26%
Operating Profit -$1.266M -$350.0K -$1.123M
YoY Change 261.71% 58.37% -1093.81%
Interest Expense $894.0K $163.0K $170.0K
YoY Change 448.47% -195.88% -206.25%
% of Operating Profit
Other Income/Expense, Net -$3.979M -$400.0K $135.0K
YoY Change 894.75% 80.18% -131.11%
Pretax Income -$5.245M -$750.0K -$988.0K
YoY Change 599.33% 69.3% 207.79%
Income Tax $605.0K -$7.000K $332.0K
% Of Pretax Income
Net Earnings -$4.064M -$1.066M -$1.320M
YoY Change 281.24% 67.61% -92.3%
Net Earnings / Revenue -15.19% -5.89% -5.0%
Basic Earnings Per Share -$0.11 -$0.03 -$0.04
Diluted Earnings Per Share -$0.11 -$0.03 -$0.04
COMMON SHARES
Basic Shares Outstanding 35.46M shares 34.58M shares 34.37M shares
Diluted Shares Outstanding 35.46M shares 34.58M shares

Balance Sheet

Concept 2018 Q1 2017 Q1 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.000M $4.600M $5.600M
YoY Change 30.43% 9.52% -16.42%
Cash & Equivalents $5.991M $4.599M $5.596M
Short-Term Investments
Other Short-Term Assets $2.959M $4.761M $4.175M
YoY Change -37.85% 9.93% 7.8%
Inventory $27.90M $20.28M $19.96M
Prepaid Expenses
Receivables $18.96M $15.48M $15.75M
Other Receivables $2.900M $4.700M $4.200M
Total Short-Term Assets $55.81M $45.10M $45.47M
YoY Change 23.75% -7.47% -10.04%
LONG-TERM ASSETS
Property, Plant & Equipment $5.821M $4.268M $4.296M
YoY Change 36.39% -25.12% -27.21%
Goodwill $56.24M $38.40M $38.03M
YoY Change 46.46% -5.13% -5.76%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.352M $144.0K $128.0K
YoY Change 838.89% 9.09% -15.79%
Total Long-Term Assets $115.1M $62.30M $62.29M
YoY Change 84.75% -9.9% -10.37%
TOTAL ASSETS
Total Short-Term Assets $55.81M $45.10M $45.47M
Total Long-Term Assets $115.1M $62.30M $62.29M
Total Assets $170.9M $107.4M $107.8M
YoY Change 59.13% -8.89% -10.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.359M $5.835M $6.196M
YoY Change 26.12% -5.46% -29.45%
Accrued Expenses $7.689M $4.324M $4.550M
YoY Change 77.82% -23.14% 13.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.400M $2.700M $2.400M
YoY Change -48.15% 12.5% 0.0%
Total Short-Term Liabilities $22.28M $14.06M $14.60M
YoY Change 58.54% -11.58% -24.44%
LONG-TERM LIABILITIES
Long-Term Debt $61.57M $10.93M $11.37M
YoY Change 463.25% -26.0% -30.51%
Other Long-Term Liabilities $6.100M $3.200M $3.200M
YoY Change 90.63% 10.34% 6.67%
Total Long-Term Liabilities $61.57M $10.93M $11.37M
YoY Change 463.25% -26.0% -30.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.28M $14.06M $14.60M
Total Long-Term Liabilities $61.57M $10.93M $11.37M
Total Liabilities $91.65M $34.68M $35.57M
YoY Change 164.27% -12.61% -16.21%
SHAREHOLDERS EQUITY
Retained Earnings -$117.2M -$116.0M
YoY Change 4.28% 3.86%
Common Stock $220.4M $216.3M $215.6M
YoY Change 1.93% 1.76% 1.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares 7.746M shares 7.746M shares 7.746M shares
Shareholders Equity $79.29M $72.72M $72.20M
YoY Change
Total Liabilities & Shareholders Equity $170.9M $107.4M $107.8M
YoY Change 59.17% -8.89% -10.23%

Cashflow Statement

Concept 2018 Q1 2017 Q1 2016 Q4
OPERATING ACTIVITIES
Net Income -$4.064M -$1.066M -$1.320M
YoY Change 281.24% 67.61% -92.3%
Depreciation, Depletion And Amortization $495.0K $306.0K $990.0K
YoY Change 61.76% -20.52% -22.05%
Cash From Operating Activities $448.0K -$610.0K $1.720M
YoY Change -173.44% -15.98% -2.82%
INVESTING ACTIVITIES
Capital Expenditures $493.0K $198.0K -$530.0K
YoY Change 148.99% -194.29% -22.06%
Acquisitions $67.41M $0.00
YoY Change
Other Investing Activities -$51.68M $1.420M
YoY Change
Cash From Investing Activities -$52.19M -$228.0K $890.0K
YoY Change 22789.91% -211.22% -230.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $219.0K -$155.0K
YoY Change -241.29% 37.17%
Debt Paid & Issued, Net $14.05M $1.113M
YoY Change 1162.08% -57.41%
Cash From Financing Activities $51.24M -$268.0K -1.210M
YoY Change -19220.9% -84.47% 4.31%
NET CHANGE
Cash From Operating Activities $448.0K -$610.0K 1.720M
Cash From Investing Activities -$52.19M -$228.0K 890.0K
Cash From Financing Activities $51.24M -$268.0K -1.210M
Net Change In Cash -$497.0K -$1.106M 1.400M
YoY Change -55.06% -50.78% -2100.0%
FREE CASH FLOW
Cash From Operating Activities $448.0K -$610.0K $1.720M
Capital Expenditures $493.0K $198.0K -$530.0K
Free Cash Flow -$45.00K -$808.0K $2.250M
YoY Change -94.43% 56.59% -8.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
193000 USD
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42763985 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35018478 shares
CY2016Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
7745507 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q1 us-gaap Other Assets Current
OtherAssetsCurrent
2959000 USD
CY2018Q1 us-gaap Assets Current
AssetsCurrent
55810000 USD
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5821000 USD
CY2018Q1 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
1102000 USD
CY2018Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1253000 USD
CY2018Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1352000 USD
CY2018Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3853000 USD
CY2018Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
538000 USD
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7689000 USD
CY2018Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1432000 USD
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
22284000 USD
CY2018Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
61569000 USD
CY2018Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1702000 USD
CY2018Q1 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
6098000 USD
CY2018Q1 us-gaap Liabilities
Liabilities
91653000 USD
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
422000 USD
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
220020000 USD
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
170947000 USD
CY2018Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
234000 USD
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43409357 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35663850 shares
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5596000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
79294000 USD
CY2018Q1 dei Trading Symbol
TradingSymbol
HBIO
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2018Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
7745507 shares
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35980459 shares
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
HARVARD BIOSCIENCE INC
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1285000 USD
CY2017Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3478000 USD
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5384000 USD
CY2018Q1 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018Q1 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5646000 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4788000 USD
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2402000 USD
CY2018Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-347000 USD
CY2017Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-143000 USD
CY2018Q1 us-gaap Interest Expense
InterestExpense
894000 USD
CY2017Q1 us-gaap Interest Expense
InterestExpense
163000 USD
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2738000 USD
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-94000 USD
CY2018Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7652000 USD
CY2018Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
4786000 USD
CY2018Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
15464000 USD
CY2018Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21772000 USD
CY2018Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15951000 USD
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3593000 USD
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2521000 USD
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1149000 USD
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1105000 USD
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1111000 USD
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
785000 USD
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
10264000 USD
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
5500000 USD
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
5700000 USD
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
5600000 USD
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
5600000 USD
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
5600000 USD
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1506000 USD
CY2017Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
942000 USD
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-254000 USD
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
4000 USD
CY2018Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
25000 USD
CY2017Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-3000 USD
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2837000 USD
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-117000 USD
CY2018Q1 hbio Total Indefinite Lived Intangible Assets Including Goodwill
TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill
57492000 USD
CY2018Q1 hbio Total Intangible Assets
TotalIntangibleAssets
132333000 USD
CY2018Q1 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
132000 USD
CY2018Q1 us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
204000 USD
CY2018Q1 us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-58000 USD
CY2018Q1 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
-14000 USD
CY2018Q1 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
415000 USD
CY2017 hbio Standard Product Warranty Accrual Decrease For Payments Or Increase For Credits
StandardProductWarrantyAccrualDecreaseForPaymentsOrIncreaseForCredits
7000 USD
CY2017 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
60000 USD
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001123494
CY2018Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
25000 USD
CY2018Q1 us-gaap Secured Debt
SecuredDebt
62982000 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19297000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15554000 USD
CY2017Q4 hbio Total Indefinite Lived Intangible Assets Including Goodwill
TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill
37580000 USD
CY2017Q4 hbio Total Intangible Assets
TotalIntangibleAssets
71616000 USD
CY2017Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
246000 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
140763 shares
CY2018Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2017Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2015Q2 hbio Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan
IncreaseInNumberOfSharesAuthorizedForIssuanceUnderStockOptionAndIncentivePlan
2500000 shares
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
34036000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-24006000 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1796927 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.69
CY2018Q1 hbio Standard Product Warranty Accrual Decrease For Payments Or Increase For Credits
StandardProductWarrantyAccrualDecreaseForPaymentsOrIncreaseForCredits
-3000 USD
CY2018Q1 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
166000 USD
CY2017Q1 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
125000 USD
CY2017Q1 us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
159000 USD
CY2017Q1 us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-87000 USD
CY2017Q1 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
53000 USD
CY2018Q1 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000 USD
CY2017Q1 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
200000 USD
CY2018Q1 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
1200000 USD
CY2017Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
1200000 USD
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4899228 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
17508929 shares
CY2017Q1 hbio Weighted Average Estimated Black Scholes Value Of Option Grants
WeightedAverageEstimatedBlackScholesValueOfOptionGrants
1.27
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q1 hbio Estimated Rental Expenses Current Year
EstimatedRentalExpensesCurrentYear
3900000 USD
CY2018Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000 USD
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.4107 pure
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0189 pure
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y2M
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10676000 USD
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9449000 USD
CY2018Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
1172000 USD
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1227000 USD
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1012000 USD
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
297874 shares
CY2018Q1 hbio Employee Stock Purchase Plan Shares Authorized
EmployeeStockPurchasePlanSharesAuthorized
1050000 shares
CY2018Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
801454 shares
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2017Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.95
CY2018Q1 us-gaap Revenues
Revenues
26759000 USD
CY2018Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13490000 USD
CY2018Q1 us-gaap Gross Profit
GrossProfit
13269000 USD
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
14535000 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1266000 USD
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3979000 USD
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5245000 USD
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
605000 USD
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2017Q1 us-gaap Depreciation
Depreciation
306000 USD
CY2017Q1 hbio Amortization Of Catalog Costs
AmortizationOfCatalogCosts
9000 USD
CY2017Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-15000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-410000 USD
CY2017Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
300000 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-110000 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-571000 USD
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
92000 USD
CY2017Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-610000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-228000 USD
CY2017Q1 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
1000000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-268000 USD
CY2017Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
109000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-997000 USD
CY2017Q1 us-gaap Interest Paid Net
InterestPaidNet
164000 USD
CY2017Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
333000 USD
CY2018Q1 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
1252000 USD
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13382000 USD
CY2017Q4 us-gaap Inventory Net
InventoryNet
16848000 USD
CY2018Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
18958000 USD
CY2018Q1 us-gaap Inventory Net
InventoryNet
27902000 USD
CY2018Q1 us-gaap Goodwill
Goodwill
56239000 USD
CY2017Q4 us-gaap Goodwill
Goodwill
36336000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10030000 USD
CY2018Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
49370000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4410000 USD
CY2018Q1 us-gaap Secured Debt Current
SecuredDebtCurrent
1413000 USD
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
7359000 USD
CY2018Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
63552000 USD
CY2018Q1 hbio Delayed Drawdown Term Loan
DelayedDrawdownTermLoan
0 USD
CY2018Q1 hbio Revolving Credit Facility
RevolvingCreditFacility
1300000 USD
CY2018Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1870000 USD
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3
CY2017Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
376000 USD
CY2018Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1103000 USD
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000 USD
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5991000 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.85 pure
CY2018Q1 hbio Percentage Of Outstanding Common Stock
PercentageOfOutstandingCommonStock
0.2 pure
CY2017Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0 shares
CY2018Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.115 pure
CY2018Q1 us-gaap Cumulative Effect On Retained Earnings Before Tax1
CumulativeEffectOnRetainedEarningsBeforeTax1
100000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4599000 USD
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5413630 shares
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
198000 USD
CY2017Q4 us-gaap Assets
Assets
109354000 USD
CY2017Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1244000 USD
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3709000 USD
CY2017Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
182000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
47535000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
324000 USD
CY2017Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
2765000 USD
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
505000 USD
CY2017Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
395000 USD
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-750000 USD
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3816000 USD
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
293000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14041000 USD
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8983000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2653000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
1466000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
28454000 USD
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
419000 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
218792000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116967000 USD
CY2017Q4 us-gaap Treasury Stock Carrying Basis
TreasuryStockCarryingBasis
10668000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109354000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5192000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
80900000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3743000 USD
CY2017Q1 us-gaap Revenues
Revenues
18086000 USD
CY2017Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8509000 USD
CY2017Q1 us-gaap Gross Profit
GrossProfit
9577000 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
9927000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-350000 USD
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-400000 USD
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2018Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 USD
CY2017Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
8404000 USD
CY2018Q1 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
0 USD
CY2017Q4 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
9960000 USD
CY2018Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 USD
CY2017Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1857000 USD
CY2018Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
0 USD
CY2017Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
1311000 USD
CY2018Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-5850000 USD
CY2017Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-743000 USD
CY2018Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
913000 USD
CY2017Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-293000 USD
CY2018Q1 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
-873000 USD
CY2017Q1 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
30000 USD
CY2018Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1786000 USD
CY2017Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-323000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-4064000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-1066000 USD
CY2018Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.16
CY2017Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.02
CY2018Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.05
CY2017Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
CY2018Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.16
CY2017Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.02
CY2018Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.05
CY2017Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.01
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35462989 shares
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34579473 shares
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35462989 shares
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34579473 shares
CY2018Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1012000 USD
CY2018Q1 us-gaap Depreciation
Depreciation
495000 USD
CY2018Q1 hbio Amortization Of Catalog Costs
AmortizationOfCatalogCosts
6000 USD
CY2018Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
5000 USD
CY2018Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
276000 USD
CY2018Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1354000 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-149000 USD
CY2018Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-799000 USD
CY2018Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-650000 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1346000 USD
CY2018Q1 us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
534000 USD
CY2017Q1 us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
4147000 USD
CY2018Q1 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
673000 USD
CY2017Q1 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
2216000 USD
CY2018Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
173000 USD
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
850000 USD
CY2018Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
429000 USD
CY2018Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-247000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
448000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-52189000 USD
CY2018Q1 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
67000000 USD
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
219000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
51244000 USD
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
755000 USD
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
258000 USD
CY2018Q1 us-gaap Interest Paid Net
InterestPaidNet
944000 USD
CY2018Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-489000 USD
CY2018Q1 hbio Additions To Catalog Costs
AdditionsToCatalogCosts
-13000 USD
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
493000 USD
CY2018Q1 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
1227000 USD
CY2017Q1 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 USD
CY2018Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
67413000 USD
CY2017Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
CY2018Q1 us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
15730000 USD
CY2017Q1 us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
0 USD
CY2018Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
14047000 USD
CY2017Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1113000 USD
CY2018Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1928000 USD
CY2017Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
CY2018Q1 us-gaap Reclassifications
Reclassifications
<div><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:27pt;' >R</font><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;' >eclassifications</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:36pt;' >As disclosed in the Note 5, on Janua</font><font style='font-family:Times New Roman;font-size:10pt;' >ry 22, 2018, the Company sold substantially all the assets of its operating subsidiary, Denville Scientific, Inc. (Denville). The sale of Denville represented a strategic shift that </font><font style='font-family:Times New Roman;font-size:10pt;' >has and will </font><font style='font-family:Times New Roman;font-size:10pt;' >have a major effect on the Company&#8217;s operations</font><font style='font-family:Times New Roman;font-size:10pt;' > and financial</font><font style='font-family:Times New Roman;font-size:10pt;' > results. As such and pursuant to Accounting Standards Codification (ASC) 205-20 &#8211; </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Presentation of Financial Statements - Discontinued Operations, </font><font style='font-family:Times New Roman;font-size:10pt;' >the </font><font style='font-family:Times New Roman;font-size:10pt;' >operating </font><font style='font-family:Times New Roman;font-size:10pt;' >results of Denville for the </font><font style='font-family:Times New Roman;font-size:10pt;' >three months ended</font><font style='font-family:Times New Roman;font-size:10pt;' > </font><font style='font-family:Times New Roman;font-size:10pt;' >March 31,</font><font style='font-family:Times New Roman;font-size:10pt;' > </font><font style='font-family:Times New Roman;font-size:10pt;' >2018</font><font style='font-family:Times New Roman;font-size:10pt;' > and </font><font style='font-family:Times New Roman;font-size:10pt;' >2017</font><font style='font-family:Times New Roman;font-size:10pt;' > have b</font><font style='font-family:Times New Roman;font-size:10pt;' >een presented in discontinued operations in the consolidated statements of operations. Additionally, t</font><font style='font-family:Times New Roman;font-size:10pt;' >he</font><font style='font-family:Times New Roman;font-size:10pt;' > assets and liabilities of Denville as of December 31, </font><font style='font-family:Times New Roman;font-size:10pt;' >2017</font><font style='font-family:Times New Roman;font-size:10pt;' > </font><font style='font-family:Times New Roman;font-size:10pt;' >have been recast </font><font style='font-family:Times New Roman;font-size:10pt;' >in the consolidated balance sheet and presented as held for sale.</font><font style='font-family:Times New Roman;font-size:10pt;' > T</font><font style='font-family:Times New Roman;font-size:10pt;' >hese reclassifications and adjustments had no effect on</font><font style='font-family:Times New Roman;font-size:10pt;' > total amounts within the</font><font style='font-family:Times New Roman;font-size:10pt;' > consolidated </font><font style='font-family:Times New Roman;font-size:10pt;' >balance sheet, </font><font style='font-family:Times New Roman;font-size:10pt;' >consolidated statements of </font><font style='font-family:Times New Roman;font-size:10pt;' >operations and </font><font style='font-family:Times New Roman;font-size:10pt;' >comprehensive loss, consolidated statements of cash flows for any of the periods presented.</font></p><p style='text-align:left;line-height:12pt;' ></p></div>
CY2018Q1 us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div><p style='text-align:left;margin-top:9pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0pt;' >2</font><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;' >.</font><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;' > Recently Issued Accounting Pronouncements</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Calibri;font-size:11pt;font-weight:bold;margin-left:0pt;' > </font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In February 2016, the </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >Financial Accounting Standards Board</font><font style='font-family:Times New Roman;font-size:10pt;' > (FASB) issued Accounting Standards Update (ASU) 2016-02, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Leases</font><font style='font-family:Times New Roman;font-size:10pt;' >, which is intended to improve financial reporting about leasing transactions. The </font><font style='font-family:Times New Roman;font-size:10pt;' >update requires a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by lease terms of more than 12&#160;months. The update is effective for fiscal years beginning after December 15, 2018. </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >The Company has com</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >menced the process of evaluating the requirements of the standard as well as collecting information on all its leases. </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >The Company has not yet concluded on the impact of the adoption on its consolidated financial position, results of operations and cash f</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >lows, however, assets and liabilities will increase upon adoption for right-of-use assets and lease liabilities.</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > The Company&#8217;s future commitments under lease obligations are summarized in Note 12.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;' >In August</font><font style='font-family:Times New Roman;font-size:10pt;' > 201</font><font style='font-family:Times New Roman;font-size:10pt;' >7, the FASB issued ASU 2017-12, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Derivatives a</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >nd Hedging (Topic 815)</font><font style='font-family:Times New Roman;font-size:10pt;' > which amends the hedge accounting recognition and presentation requirements in ASC 815. The Board&#8217;s objectives in issuing the ASU are to (1) improve the transparency and understandability of information conveyed to financial statemen</font><font style='font-family:Times New Roman;font-size:10pt;' >t users about an entity&#8217;s risk management activities by better aligning the entity&#8217;s financial reporting for hedging relationships with those risk management activities and (2) reduce the complexity of and simplify the application o</font><font style='font-family:Times New Roman;font-size:10pt;' >f hedge accounting by pr</font><font style='font-family:Times New Roman;font-size:10pt;' >eparers. The</font><font style='font-family:Times New Roman;font-size:10pt;' > ASU is effective for annual reporting periods, including interim periods within those annual reporting periods, beginning after December 15, 201</font><font style='font-family:Times New Roman;font-size:10pt;' >8</font><font style='font-family:Times New Roman;font-size:10pt;' >. Early adoption is permitted, including adoption in any interim period.</font><font style='font-family:Times New Roman;font-size:10pt;' > </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >The Company is evaluating</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > the requirements of this guidance and has not yet determined the impact of the adoption on its consolidated financial position, results of operations and cash flows.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:24.5pt;' >Recently Adopted Accounting Pronouncements</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >&#160;</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >In May 2014, the FASB issued ASU 2014-09,&#160;</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;color:#000000;' >R</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;color:#000000;' >evenue from Contracts with Customers,&#160;</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance within generally</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > accepted accounting principles in the United States. Under this standard, revenue will be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > in exchange for those goods or services.</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >&#160;</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >The Company adopted this standard as of January 1, 2018 using the modified retrospective approach, and applied the guidance to contracts that were not completed at the date of adoption. The Company&#8217;s significant </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >revenue streams currently consist primarily of product revenue transactions, service, maintenance and extended warranty transactions on certain product sales. </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >The timing of recognizing revenues for these revenue streams did not materially change. Additiona</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >lly, the adoption of ASU&#160;</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >2014</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >-</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >09</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >&#160;did&#160;</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >not</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >&#160;have a material impact on the Company&#8217;s financial position, results of operations, equity or cash flows as of the adoption date or for the&#160;</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >three</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >&#160;months ended&#160;</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >March 31, 2018.&#160;</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >The Company&#8217;s updated revenue recognition</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > policy is described in Note 1 and disaggregated revenue disclosures required under ASC 2014-09 are presented in Note 17. </font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >&#160;</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:22.5pt;color:#000000;' >In May 2017, the FASB issued ASU 2017-09,&#160;Stock compensation (Topic 718): Scope of modification accounting&#160;which amends the scope o</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >f modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >Specifically, an entity would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The ASU is effective for annual reporting periods, including</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > interim periods within those annual reporting periods, beginning after December 15, 2017. </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >The Company adopted this guidance on January 1, 2018, and the new standard did not have a material impact on its consolidated financial position, results of operatio</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >ns and cash flows.</font></p><p style='text-align:left;line-height:12pt;' ></p></div>
CY2018Q1 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
70000000 USD
CY2018Q1 us-gaap Business Acquisition Description Of Acquired Entity
BusinessAcquisitionDescriptionOfAcquiredEntity
DSI, a St. Paul, Minnesota-based life science research company, is a recognized leader in physiologic monitoring focused on delivering preclinical products, systems, services and solutions to its customers.
CY2018Q1 us-gaap Business Acquisition Effective Date Of Acquisition1
BusinessAcquisitionEffectiveDateOfAcquisition1
2018-01-31
CY2018Q1 hbio Amortization Period Of Purchase Accounting Inventory Fair Value Step Up Amortization
AmortizationPeriodOfPurchaseAccountingInventoryFairValueStepUpAmortization
P5M
CY2018Q1 us-gaap Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual
BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
7600000 USD
CY2018Q1 us-gaap Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual
BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
400000 USD
CY2018Q1 hbio Busniess Combination Purchase Accounting Inventory Fair Value Step Up Amortization
BusniessCombinationPurchaseAccountingInventoryFairValueStepUpAmortization
1500000 USD
CY2018Q1 hbio Preliminary Amount Of Inventory Fair Value Step Up
PreliminaryAmountOfInventoryFairValueStepUp
3800000 USD
CY2018Q1 hbio Business Combination Proforma Information Amortization Of Intangible Asets
BusinessCombinationProformaInformationAmortizationOfIntangibleAsets
700000 USD
CY2018Q1 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
2600000 USD
CY2017Q1 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
0 USD
CY2018Q1 hbio Discontinued Operation Name
DiscontinuedOperationName
Denville
CY2018Q1 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
20000000 USD
CY2018Q1 hbio Earn Out Provision Of Discontinued Operations
EarnOutProvisionOfDiscontinuedOperations
3000000 USD
CY2018Q1 hbio Discontinued Operation Earn Out Amount Contingent Consideration
DiscontinuedOperationEarnOutAmountContingentConsideration
3000000 USD
CY2018Q1 hbio Earn Out Performance Metrics Period
EarnOutPerformanceMetricsPeriod
P2Y
CY2017Q4 us-gaap Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
541000 USD
CY2017Q4 us-gaap Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net
DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
2854000 USD
CY2017Q4 us-gaap Disposal Group Including Discontinued Operation Inventory Current
DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
4505000 USD
CY2017Q4 us-gaap Disposal Group Including Discontinued Operation Other Current Assets
DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets
504000 USD
CY2017Q4 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment Noncurrent
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
397000 USD
CY2017Q4 us-gaap Disposal Group Including Discontinued Operation Intangible Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
5930000 USD
CY2017Q4 us-gaap Disposal Group Including Discontinued Operation Goodwill Noncurrent
DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent
3633000 USD
CY2017Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
18364000 USD
CY2017Q4 us-gaap Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities Current
DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent
1736000 USD
CY2017Q4 us-gaap Disposal Group Including Discontinued Operation Other Current Liabilities
DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
121000 USD
CY2017Q4 us-gaap Disposal Group Including Discontinued Operation Deferred Tax Liabilities Noncurrent
DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilitiesNoncurrent
1311000 USD
CY2018Q1 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
1227000 USD
CY2017Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
3168000 USD
CY2018Q1 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
893000 USD
CY2017Q1 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
6070000 USD
CY2017Q1 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
0 USD
CY2018Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
18731000 USD
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5779000 USD
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1042000 USD
CY2017Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
10027000 USD
CY2018Q1 us-gaap Defined Benefit Plan Expected Future Employer Contributions Remainder Of Fiscal Year
DefinedBenefitPlanExpectedFutureEmployerContributionsRemainderOfFiscalYear
500000 USD
CY2018Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-12-31
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
863000 USD
CY2018Q1 hbio Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan
IncreaseInNumberOfSharesAuthorizedForIssuanceUnderStockOptionAndIncentivePlan
300000 shares
CY2018Q1 us-gaap Deferred Compensation Arrangement With Individual Maximum Contractual Term1
DeferredCompensationArrangementWithIndividualMaximumContractualTerm1
P10Y
CY2018Q1 hbio Amortization Of Intangible Assets Including Amounts Related To Discontinued Operation
AmortizationOfIntangibleAssetsIncludingAmountsRelatedToDiscontinuedOperation
1150000 USD
CY2017Q1 hbio Amortization Of Intangible Assets Including Amounts Related To Discontinued Operation
AmortizationOfIntangibleAssetsIncludingAmountsRelatedToDiscontinuedOperation
599000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
5733000 USD
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
5596000 USD
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
5991000 USD
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
4599000 USD
CY2018Q1 hbio Preferred Stock Purchase Right Option Exercised
PreferredStockPurchaseRightOptionExercised
0 shares
CY2018Q1 us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
The Shareholder Rights Plan expired, with no rights having become exercisable, in accordance with its terms on the close of business on February 6, 2018.
CY2018Q1 hbio Maximum Percentage Of Target Number Of Restricted Stock Units
MaximumPercentageOfTargetNumberOfRestrictedStockUnits
1.5 pure
CY2017Q4 us-gaap Secured Debt
SecuredDebt
11748000 USD
CY2017Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
11899000 USD
CY2017Q4 hbio Delayed Drawdown Term Loan
DelayedDrawdownTermLoan
0 USD
CY2017Q4 hbio Revolving Credit Facility
RevolvingCreditFacility
0 USD
CY2017Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
151000 USD
CY2018Q1 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
387000 USD
CY2017Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
35000 USD
CY2018Q1 us-gaap Loans Payable Current
LoansPayableCurrent
1800000 USD
CY2017Q4 us-gaap Loans Payable Current
LoansPayableCurrent
2800000 USD
CY2018Q1 us-gaap Line Of Credit
LineOfCredit
11900000 USD
CY2018Q1 us-gaap Debt Instrument Payment Terms
DebtInstrumentPaymentTerms
the outstanding term loans amortize in equal quarterly installments equal to $0.4 million per quarter on such date and during each of the next three quarters thereafter, $0.6 million per quarter during the next four quarters thereafter and $0.8 million per quarter thereafter, with a balloon payment at maturity.
CY2018Q1 hbio Debt Instrument Quarterly Payment Current Year
DebtInstrumentQuarterlyPaymentCurrentYear
400000 USD
CY2018Q1 hbio Debt Instrument Quarterly Payment Next Year
DebtInstrumentQuarterlyPaymentNextYear
600000 USD
CY2018Q1 hbio Debt Instrument Quarterly Payment Thereafter
DebtInstrumentQuarterlyPaymentThereafter
800000 USD
CY2018Q1 us-gaap Debt Instrument Term
DebtInstrumentTerm
P5Y
CY2018Q1 hbio Limitation On Pledges Of Capital Stock Of Foreign Subsidiaries
LimitationOnPledgesOfCapitalStockOfForeignSubsidiaries
0.65 pure
CY2018Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
25000000 USD
CY2016Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
193000 USD
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
193000 USD
CY2018Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
5000 USD
CY2018Q1 hbio Allowance For Doubtful Accounts Receivable Other
AllowanceForDoubtfulAccountsReceivableOther
36000 USD
CY2018Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
234000 USD
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2018Q1 hbio Effective Income Tax Rate Reconciliation Reduction In Tax Rate From Tax Cuts And Jobs Act Of2017
EffectiveIncomeTaxRateReconciliationReductionInTaxRateFromTaxCutsAndJobsActOf2017
0.21 pure
CY2017Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.01 pure

Files In Submission

Name View Source Status
0001171843-18-003819-index-headers.html Edgar Link pending
0001171843-18-003819-index.html Edgar Link pending
0001171843-18-003819.txt Edgar Link pending
0001171843-18-003819-xbrl.zip Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
exh_322.htm Edgar Link pending
f10q_050918.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hbio-20180331.xml Edgar Link completed
hbio-20180331.xsd Edgar Link pending
hbio-20180331_cal.xml Edgar Link unprocessable
hbio-20180331_def.xml Edgar Link unprocessable
hbio-20180331_lab.xml Edgar Link unprocessable
hbio-20180331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending